Curtis C. Harris

Last updated

Curtis C. Harris
Curt Profile II.png
Harris in 2020
Born
EducationB.A., University of Kansas (1965); M.D., University of Kansas School of Medicine (1969); Intern Certificate, Internal Medicine, U.C.L.A. Hospital, Los Angeles (1970), CA; Resident Certificate, Internal Medicine, V.A. Hospital, Washington, DC (1976)
Alma mater University of Kansas
Known forp53, Molecular Epidemiology, Cancer Metabolome, Molecular basis of Cancer, Precision Cancer Medicine
SpouseTance Harris
ChildrenBrent Harris, Jill Harris, Todd Harris and Megan Harris
AwardsMember, board of directors (1984), American Association for Cancer Research; Fellow of the American Society for Clinical Investigation (1995); Walter Hubert Award: British Association for Cancer Research (1995); Lewis M. Schiffer Memorial Award and Lecturer Cell Proliferation Society (1996); Bob Champion Award and Lecturer British Oncological Association (1996); Distinguished Service Medal (1999), highest award of the US Public Health Service; Award of Merit Princess Takamatsu Cancer Research Foundation (2002); Fellow of the American Association for the Advancement of Science (2003); NCI Outstanding Mentor Award (2007); NIH MERIT Award (2009); AACR-Princess Takamutsu Award (2009); AACR Cancer Epidemiology Biomarkers and Prevention Award (2014); University of Kansas School of Medicine award recipient (2016) Environment Mutagenesis and Genome Society Award (2020); Fellow, Academy of AACR (2021)
Scientific career
Fields Cancer Research, molecular epidemiology
Institutions National Cancer Institute, Laboratory of Human Carcinogenesis
Website ccr.cancer.gov/Laboratory-of-Human-Carcinogenesis/curtis-c-harris

Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.

Contents

Harris graduated from University of Kansas with a BA in zoology in 1965, and an MD in 1969. [1] He was an internal medicine intern at UCLA hospital in 1969. He did research and completed his medical oncology training at NCI and Washington Veterans Hospital. Since 1981, he has been head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis. [1] He is also a lecturer of medicine and oncology at Georgetown University School of Medicine. He has published more than 700 journal articles and has been awarded 30 patents. [2]

His current research focuses on Precision Medicine of Cancer and Aging. [3] His research career has focused on environmental, genetic and epigenomic causes of human carcinogenesis.

He is also a co-author of the international spy novel High Hand using a pseudonym Curtis J. James. [4] [5]

Research

Harris has made many major discoveries in cancer research. One of the most notable is his seminal work describing the first-known molecular link between an environmental carcinogen, aflatoxin B1, and a specific mutation at codon 249 of the p53-encoding TP53 gene in hepatocellular carcinoma (Nature 350:427, 1991 and web of science). [6] This discovery was selected by the AACR as a Centennial Landmark in Cancer Research. In addition, his paper on the TP53 mutation spectrum is among the most highly cited in the biomedical research field, with over 9,000 citations and web of science (Science 253:49, 1991). [7] These findings have had, and continue to have, a major impact in cancer risk assessment and biomarker discovery for cancer prevention, diagnosis and prognosis.

Harris's research has investigated mechanistic, translational, and functional links between population and basic science research. When the focus of cancer research was on in human vitro and in vitro animal models, he pioneered investigations of carcinogen metabolism, DNA damage, and DNA repair and mutagenesis in humans and in human tissues (e.g., Science 194:1067, 1976; Cancer Res 44:2855, 1984). [8] [9] Many of these studies were among the first to highlight the deleterious effects of tobacco carcinogens and their damage to human health (e.g., Cancer Res. 33: 2842–2848, 1973; Nature 247: 48–49, 1974, Nature 252: 68–69, 1974), providing an evidence base for tobacco control policies. Moreover, he led the development of first-in-kind in vitro models of human bronchial epithelial cells from patient explants (e.g., Cancer Res. 36: 1003–1010, 1976, Nature 252: 68–69, 1974). [10] [11] In parallel, he has extensively investigated p53 functions in the regulation of DNA repair, apoptosis, senescence, and tumorigenicity (e.g., Nat Genet. 10:188, 1995; Nat Med. 4:137,1998; Nat Cell Biol 11:1135, 2009; Nat Cell Biol, 12: 1205, 2010) [12] and recently a microbiome – TP53 mutation interaction in human lung cancer, Genome Biology:19: 123–29, 2018. [13]

Decades prior to the recent discovery of mutant TP53 cells in esophageal tissue (Cell Stem Cell 25:321-41, 2019; Science 362:911-17, 2018), Drs. Peter Cerruti and Curtis Harris, using the novel and highly sensitive TP53 mutational load assay, discovered TP53 mutant DNA in non-malignant lung and plasma in tobacco smokers (PNAS 97: 12770–5, 2000; Science 264: 1317–19, 1994; Cancer Res. 66: 8309–17, 2000). In the past decade, Harris has contributed substantially to research on TP53 mutations, as well as TP53 isoforms and their effects on senescence, aging and cancer (Fujita K, et al., Nat Cell Biol 11:1135–41, 2009; Mondal A, et al., J Clin Invest 123:5247-57, 2013; Turnquist C. et al., Cell Death Differ 23: 1515–28,2016; Hirokawa I. et al., Cell Death Differ 24: 1017–28, 2017; Von Muhlinen N., et al., Oncogene 37: 2379–93, 2018; Mondal, AM. et al., Cell Death and Dis 9: 750–804, 2018; Turnquist C. et al., Neuro Oncology 21: 474–85, 2019).

Translational Discoveries in Cancer Biomarkers: Harris's research aims to identify mechanistic and statistically independent biomarkers of cancer risk, diagnosis, prognosis, and therapeutic outcomes, using data from multiple ethnic and geographic cohorts. One mechanistic facet of these studies is chronic inflammation, a feature of the internal exposome (initially described by Chris Wild, Cancer Epi Biomarkers Prev 14: 1847, 2005) [14] and an established cancer risk factor. He reported findings that increased levels of circulating interleukins are predictors of cancer risk, diagnosis, and prognosis of lung cancer patients (JNCI 99:1401, 2007; JNCI 103:1112, 2011). [15] He also identified microRNAs associated with both diagnosis and prognosis of lung cancer (Cancer Cell 9:189, 2006; Clin Cancer Res 17: 1875, 2011) and prognosis and therapeutic outcome of colon cancer (JAMA 299:425, 2008). In addition, he reported that combinations of DNA methylation, microRNAs, and proteins (e.g. inflammation-related) produced by human lung, colon, and esophageal carcinomas are robust cancer prognostic classifiers (PNAS 106:12085, 2009; Clin Cancer Res 15:5878, 2009; Clin Cancer Res 15:6192, 2009; Clin Cancer Res 16:5824, 2010; Clin Cancer Res 17:1875, 2011; Int J Cancer 132:2901, 2013; Cancer Res 73:3821, 2013, J of Thoracic Oncology, 10: 1037–1048, 2015). Importantly, these studies identified early-stage lung and colon cancers that have poor prognoses due to the likelihood of undetected micrometastasis.

Over the past ten years, Harris has conducted several novel studies of the human metabolome and how it contributes to cancer risk assessment, cancer diagnosis and the accurate identification of early stage lung cancer patients at high-risk of tumor recurrence (Cancer Res. 74: 3259–3270, 2014; Cancer Epidemiology, Biomarkers & Prevention 25(6); 978–86, 2016).

Accomplishments

Accolades include the Biomarker and Prevention Award, AACR Princess Takamatsu Award, the Oschner Award relating to Smoking and Health from the American College of Physicians, the Deichmann Award from the International Union of Toxicology, the Environment Mutagenesis and Genome Award, and the Distinguished Service Medal—the highest honor of the U.S. Public Health Service.

Harris has been an expert witness at hearings concerning OSHA Regulations on the Identification, Classification and Regulation of Toxic Substances Posing a Potential Occupational Carcinogenic Risk, a member of the technical review committee for the USPHS Surgeon General Report on Harmful Effects of Smokeless Tobacco and was a contributing a to the Surgeon General's 2004 seminal report on the Health Consequences of Smoking. Harris has also been a member of the Scientific Advisory Council at IARC. Moreover, he has demonstrated a steadfast from the 1980s to the present commitment on the Advisory Committee and honored consultant to the Radiation Effects Research Foundation in Hiroshima Japan, an organization dedicated to understanding the health consequences of radiation exposure among survivors of atomic bombs. Harris cofounded the Aspen Cancer Conference, [16] a non-profit organization, in 1985 with Dr. Ben Trump where he serves as chairman of the board of directors.

Harris's published research has over 90,000 citations and H-index of over 140.[ citation needed ] Harris has served as Chairman of the Program Committee of the AACR Annual Meeting; member of the AACR's board of directors, Nominating Committee and many Award Committees; and chairman of the board of directors and Chairman of the Scientific Program Advisory Board for the Keystone Symposia on Molecular and Cellular Biology. He is also since 1984 to recent the Editor-in Chief of the journal Carcinogenesis.[ citation needed ]

List of accolades

Related Research Articles

p53 Mammalian protein found in humans

p53, also known as Tumor protein P53, cellular tumor antigen p53, or transformation-related protein 53 (TRP53) is a regulatory protein that is often mutated in human cancers. The p53 proteins are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene.

<span class="mw-page-title-main">Tumor suppressor gene</span> Gene that inhibits expression of the tumorigenic phenotype

A tumor suppressor gene (TSG), or anti-oncogene, is a gene that regulates a cell during cell division and replication. If the cell grows uncontrollably, it will result in cancer. When a tumor suppressor gene is mutated, it results in a loss or reduction in its function. In combination with other genetic mutations, this could allow the cell to grow abnormally. The loss of function for these genes may be even more significant in the development of human cancers, compared to the activation of oncogenes.

<span class="mw-page-title-main">Li–Fraumeni syndrome</span> Autosomal dominant cancer syndrome

Li–Fraumeni syndrome is a rare, autosomal dominant, hereditary disorder that predisposes carriers to cancer development. It was named after two American physicians, Frederick Pei Li and Joseph F. Fraumeni Jr., who first recognized the syndrome after reviewing the medical records and death certificates of 648 childhood rhabdomyosarcoma patients. This syndrome is also known as the sarcoma, breast, leukaemia and adrenal gland (SBLA) syndrome.

Carcinogenesis, also called oncogenesis or tumorigenesis, is the formation of a cancer, whereby normal cells are transformed into cancer cells. The process is characterized by changes at the cellular, genetic, and epigenetic levels and abnormal cell division. Cell division is a physiological process that occurs in almost all tissues and under a variety of circumstances. Normally, the balance between proliferation and programmed cell death, in the form of apoptosis, is maintained to ensure the integrity of tissues and organs. According to the prevailing accepted theory of carcinogenesis, the somatic mutation theory, mutations in DNA and epimutations that lead to cancer disrupt these orderly processes by interfering with the programming regulating the processes, upsetting the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. Only certain mutations lead to cancer whereas the majority of mutations do not.

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 52,000 members in 130 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

<span class="mw-page-title-main">Bert Vogelstein</span> American oncologist (born 1949)

Bert Vogelstein is director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center. A pioneer in the field of cancer genomics, his studies on colorectal cancers revealed that they result from the sequential accumulation of mutations in oncogenes and tumor suppressor genes. These studies now form the paradigm for modern cancer research and provided the basis for the notion of the somatic evolution of cancer.

Philip C. Hanawalt is an American biologist who discovered the process of repair replication of damaged DNA in 1963. He is also considered the co-discoverer of the ubiquitous process of DNA excision repair along with his mentor, Richard Setlow, and Paul Howard-Flanders. He holds the Dr. Morris Herzstein Professorship in the Department of Biology at Stanford University, with a joint appointment in the Dermatology Department in Stanford University School of Medicine.

Karen Heather Vousden, CBE, FRS, FRSE, FMedSci is a British medical researcher. She is known for her work on the tumour suppressor protein, p53, and in particular her discovery of the important regulatory role of Mdm2, an attractive target for anti-cancer agents. From 2003 to 2016, she was the director of the Cancer Research UK Beatson Institute in Glasgow, UK, moving back to London in 2016 to take up the role of Chief Scientist at CRUK and Group Leader at the Francis Crick Institute.

<span class="mw-page-title-main">Joseph F. Fraumeni Jr.</span> American physician and cancer researcher

Joseph F. Fraumeni Jr. is an American physician and cancer researcher. Born in Boston, he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.

Maureen E. Murphy is an American cancer researcher who works at The Wistar Institute in Philadelphia. Her research focuses on the tumor suppressor genes p53 and the cancer survivor protein HSP70. Previously, she was a faculty member at the Fox Chase Cancer Center from 1998 until moving to The Wistar Institute in 2011.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

<span class="mw-page-title-main">Scott W. Lowe</span> American geneticist

Scott William Lowe is Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is recognized for his research on the tumor suppressor gene, p53, which is mutated in nearly half of cancers.

Professor Carol L. Prives FRS is the Da Costa Professor of Biological Sciences at Columbia University. She is known for her work in the characterisation of p53, an important tumor suppressor protein frequently mutated in cancer.

Guillermina 'Gigi' Lozano is an American geneticist. She is a professor at University of Texas MD Anderson Cancer Center. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression.

<span class="mw-page-title-main">Henri Rochefort (physician)</span> French cancer physician

Henri Rochefort is a French biochemical doctor, born on 20 November 1935 in Paris, who studied the influence of various hormones and their antagonists on breast and ovarian cancers. He is a corresponding member of the French Academy of sciences.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.

Laura Attardi is the Catharine and Howard Avery Professor of the school of medicine, and professor of radiation oncology and genetics at Stanford University where she leads the Attardi Laboratory. Attardi studies the tumor suppressor protein p53 and the gene that encodes it, TP53, to better understand mechanisms for preventing cancer.

<span class="mw-page-title-main">Lawrence A. Loeb</span> American scientist and cancer researcher

Lawrence A. "Larry" Loeb is an American cancer researcher and genome scientist. He is a professor of pathology and biochemistry at the University of Washington. Loeb is best known for his work on the fidelity of DNA polymerase, and his proposal of the mutator phenotype hypothesis in cancers.

References

  1. 1 2 "Biosketch L Curtis C. Harris, MD" (PDF). Uc.pt. Retrieved January 17, 2017.
  2. "Laboratory of Human Carcinogenesis". n.d. Archived from the original on January 18, 2017. Retrieved March 13, 2020.
  3. "Curtis C. Harris, MD". Kerafast.com. n.d. Retrieved January 17, 2017.
  4. "Novel's Authors To Sign 'High Hand' in Clarendon". connectionnewspapers.com.
  5. "Featured Authors – Copper Peak Press". Copperpeakpress.com. n.d. Archived from the original on August 26, 2018. Retrieved March 13, 2020.
  6. Hsu, I., Metcalf, R., Sun, T. et al. Mutational hot spot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427–428 (1991). https://doi.org/10.1038/350427a0
  7. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. (1991). "P53 mutations in human cancers". Science. 253 (5015): 49–53. doi:10.1126/science.1905840. PMID   1905840.
  8. Harris, C. C.; Autrup, H.; Connor, R.; Barrett, L. A.; McDowell, E. M.; Trump, B. F. (December 3, 1976). "Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi". Science. 194 (4269): 1067–1069. doi:10.1126/science.982061. PMID   982061.
  9. Izumu, I., Mineura, K., Watanabe, K. et al. Characterization and chemosensitivity of two cell lines derived from human glioblastomas. J Neuro-Oncol 17, 111–121 (1993). https://doi.org/10.1007/BF01050213
  10. "Journal" (PDF). cancerres.aacrjournals.org. n.d. Retrieved March 13, 2020.
  11. Pashin, Y. V.; Bakhitova, L. M. (1979). "Mutagenic and carcinogenic properties of polycyclic aromatic hydrocarbons". Environmental Health Perspectives. 30: 185–189. doi:10.1289/ehp.7930185. PMC   1637690 . PMID   446450.
  12. Nat Genet. 10:188
  13. Greathouse, K. Leigh; White, James R.; Vargas, Ashely J.; Bliskovsky, Valery V.; Beck, Jessica A.; von Muhlinen, Natalia; Polley, Eric C.; Bowman, Elise D.; Khan, Mohammed A.; Robles, Ana I.; Cooks, Tomer; Ryan, Bríd M.; Padgett, Noah; Dzutsev, Amiran H.; Trinchieri, Giorgio; Pineda, Marbin A.; Bilke, Sven; Meltzer, Paul S.; Hokenstad, Alexis N.; Stickrod, Tricia M.; Walther-Antonio, Marina R.; Earl, Joshua P.; Mell, Joshua C.; Krol, Jaroslaw E.; Balashov, Sergey V.; Bhat, Archana S.; Ehrlich, Garth D.; Valm, Alex; Deming, Clayton; et al. (2018). "Interaction between the microbiome and TP53 in human lung cancer". Genome Biology. 19 (1): 123. doi: 10.1186/s13059-018-1501-6 . PMC   6109311 . PMID   30143034.
  14. Wild, Christopher Paul (August 1, 2005). "Complementing the Genome with an "Exposome": The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology". Cancer Epidemiology, Biomarkers & Prevention. 14 (8): 1847–1850. doi: 10.1158/1055-9965.EPI-05-0456 . PMID   16103423 via cebp.aacrjournals.org.
  15. "Lung Cancer" (PDF). ccr.cancer.gov. 2017. Retrieved March 13, 2020.
  16. "Aspen Cancer Conference". Aspen Cancer Conference.
  17. "The American Society for Clinical Investigation".
  18. "American Association for Cancer Research (AACR)". American Association for Cancer Research (AACR).
  19. "Public Health Service Distinguished Service Medal".
  20. "AACR Princess Takamatsu Memorial Lectureship: Past Recipients".
  21. "AAAS Home". American Association for the Advancement of Science.
  22. "cct-mentor-award (Previous Winners) | Events Registration". events.cancer.gov.
  23. "EMGS : Environmental Mutagenesis and Genomics Society". emgs-us.org.